Trials / Completed
CompletedNCT00375193
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
A Phase 2 Trial of Single-Agent Amrubicin in Patients With Extensive Disease Small Cell Lung Cancer That is Refractory or Progressive Within 90 Days of Completion of First Line Platinum-based Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amrubicin | Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-05-01
- Completion
- 2009-03-01
- First posted
- 2006-09-12
- Last updated
- 2019-10-24
Locations
46 sites across 3 countries: United States, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00375193. Inclusion in this directory is not an endorsement.